Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Company Overview
Harrow Health Inc (HROW) is an innovative eyecare pharmaceutical company focused on addressing unmet medical needs through the discovery, development, production, and commercialization of specialized ophthalmic formulations and therapeutic products across the United States. Operating at the intersection of advanced research and clinical application, the company brings together deep industry expertise, rigorous R&D, and a commitment to improving patient care.
Business Model and Operations
At its core, Harrow Health provides a comprehensive portfolio that blends ophthalmology-based drug development with non-intravenous sedation and anesthesia therapeutics for a variety of medical procedures. Its operations are structured around:
- Ophthalmic Therapeutics: Focusing on the management of ocular surface diseases, the company develops topical eye drop formulations that serve both preventative and therapeutic roles.
- Compounded Medications: Offering both sterile and non-sterile formulations, it meets the needs of physicians seeking tailored solutions for diverse clinical scenarios.
- Non-Intravenous Sedation: Developing products designed to facilitate conscious sedation during procedures such as cataract surgery, thereby enhancing patient comfort and procedural efficiency.
This multi-pronged approach not only diversifies its product portfolio but also creates a resilient business model that appeals to healthcare professionals and institutions across outpatient, in-office, and hospital settings.
Market Position and Competitive Landscape
Harrow Health Inc has carved a niche within the highly regulated US pharmaceutical market. Its strategic focus on ocular and sedation therapeutics differentiates it from broader scale pharmaceutical companies, while its commitment to advanced research and quality production standards reinforces its reputation among eyecare professionals. In a competitive landscape where precision and safety are paramount, Harrow Health’s integration of clinical insights with innovative drug formulations positions it as a noteworthy player devoted to addressing specific medical challenges effectively.
Product Portfolio and Therapeutic Solutions
The company has developed an extensive range of products that address conditions related to the ocular surface and procedural sedation. Its portfolio includes:
- Topical Ophthalmic Formulations: Designed to manage diseases affecting the ocular surface and support rehabilitation of vision-related functions.
- Compounded Medications: Both sterile and non-sterile, these are tailored to meet precise medical requirements across various treatment settings.
- Sedation Therapeutics: Products intended for sublingual administration provide non-intravenous sedation, enabling safe and effective patient management during surgical procedures.
Research, Development, and Quality Assurance
The foundation of Harrow Health Inc’s operations lies in robust research and development. The company continually refines its product offerings through comprehensive clinical research and adherence to stringent quality assurance protocols. Its approach underscores a commitment to safety and efficacy while addressing the evolving needs of healthcare providers and patients. This rigorous scientific methodology exemplifies the company’s dedication to maintaining high standards of regulatory compliance and industry best practices.
Commitment to Scientific Integrity and Patient Care
Across its diverse operations, Harrow Health demonstrates a sustained commitment to improving patient outcomes. The company’s emphasis on continuous innovation, strategic R&D, and quality-focused manufacturing processes helps ensure that its pharmaceutical solutions not only meet but often exceed industry benchmarks. This dedication to scientific integrity and patient well-being has established Harrow Health as a trusted entity within the field of eyecare therapeutics.
Strategic Value Proposition
Harrow Health Inc’s value proposition is rooted in its specialized expertise in ophthalmic formulations and sedation therapies. By addressing critical gaps in current medical treatments, the company supports healthcare providers in delivering effective and accessible care. Its balanced focus on innovation, quality, and clinical relevance positions it as a vital contributor to the pharmaceutical landscape, particularly within the realms of eye care and procedural sedation.
Overall, Harrow Health Inc exemplifies a dedicated, research-driven approach to pharmaceutical development that leverages deep industry expertise to meet unmet medical needs. Through its integrated operations and commitment to quality, it remains a significant, unbiased source of therapeutic solutions for healthcare professionals nationwide.
Harrow (HROW) announced a favorable jury verdict in a trademark infringement case where its subsidiary ImprimisRx sued OSRX, Inc. and Ocular Science, Inc. The eight-person jury unanimously found the defendants guilty of willful trademark infringement and unfair competition, awarding $34.9 million in damages. The verdict includes $20.4 million in punitive damages and $14.5 million in actual damages. The case was tried in the United States District Court for the Southern District of California, where the jury validated ImprimisRx's trademark estate and found the defendants acted with malice, fraud, or oppression.
Melt Pharmaceuticals announced positive Phase 3 topline results for MELT-300, a non-IV, non-opioid sublingual tablet for procedural sedation during cataract surgery. The study, involving over 530 patients across 13 U.S. clinical sites, demonstrated MELT-300's statistical superiority over both sublingual midazolam (P=0.009) and placebo (P<0.001). The tablet combines midazolam (3mg) and ketamine (50mg), dissolving in 3 seconds using Catalent's Zydis® technology. Patients receiving midazolam alone required nearly twice the rescue sedation compared to MELT-300 (P=0.003), while MELT-300 showed a favorable safety profile comparable to placebo.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in three upcoming investor conferences. The company will attend the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, the BTIG 4th Annual Ophthalmology Day on December 2, 2024, and the Piper Sandler 36th Annual Healthcare Conference from December 3-5, 2024.
Management will conduct one-on-one meetings at all conferences. A Fireside Chat is scheduled for December 4, 2024, at 8:00 a.m. ET during the Piper Sandler conference, which will be the only event featuring an audio webcast available on Harrow's website.
Harrow (HROW) reported strong Q3 2024 results with revenues increasing 44% year-over-year to $49.3 million. The company posted a GAAP net loss of $(4.2) million and Adjusted EBITDA of $8.8 million. Key highlights include a 55% increase in VEVYE prescriptions over Q2 2024, 15% growth in IHEEZO customer unit demand, and operating cash flow of $3 million. The company maintained strong cash position with $72.6 million in cash and equivalents. Despite Q3 seasonal challenges, management expects Q4 revenue to meaningfully exceed 2024 guidance, driven by positive demand trends for VEVYE, IHEEZO, and TRIESENCE products.
Harrow (HROW) announced a new initiative to improve access and affordability of its ophthalmic pharmaceutical products through two main strategies. First, the company is implementing price reductions for several products, starting with VIGAMOX® and MAXIDEX®. Second, Harrow established a partnership with GoodRx to provide discounted pricing for seven products including FLAREX®, ILEVRO®, MAXIDEX®, TOBRADEX® ST, VEVYE®, VIGAMOX®, and ZERVIATE® through GoodRx's platform, particularly benefiting uninsured and underinsured patients.
Harrow (HROW) has secured significant market access for VEVYE in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in formularies managed by Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark, reaching over 25 million Medicare Part D beneficiaries. The drug has achieved coverage across 100% of U.S. Medicaid programs and 60% of commercial insurance coverage. This expansion particularly benefits older adults among the 67 million Medicare beneficiaries, including 54 million with Part D coverage, who are at increased risk for chronic dry eye disease (DED).
Harrow (HROW) has announced a nationwide launch of a digital patient access solution in partnership with Asembia, aiming to expand access to Harrow's ophthalmic branded products. The collaboration leverages ASPN Pharmacies, Asembia's non-dispensing pharmacy, to streamline prescription processes and improve medication accessibility and affordability. The service includes benefits verification, prior authorization, co-pay support, and patient assistance program eligibility. Healthcare providers can order through their EHR/EMR platforms or the ASPN provider portal, which allows multiple Harrow products to be ordered simultaneously.
Harrow (Nasdaq: HROW), a North American eyecare pharmaceutical company, has scheduled its third quarter 2024 financial results announcement for November 13, 2024, after market close. The company will publish its quarterly Letter to Stockholders on its website and host a conference call with a business update on November 14, 2024, at 8:00 a.m. Eastern Time. Interested participants can join via webcast through Harrow's website or by telephone after registering in advance.
Melt Pharmaceuticals has announced the completion of patient dosing in its pivotal Phase 3 study for MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The study, conducted at 13 clinical sites with over 525 patients, compares MELT-300 to sublingual midazolam and placebo. Topline results are expected by the end of 2024.
The FDA has agreed to a Special Protocol Assessment (SPA) for the MELT-300 Phase 3 study, establishing a binding agreement on key elements for a future marketing application. Additionally, a cardiac safety study showed MELT-300 does not alter normal heart rhythm.
MELT-300 combines fixed doses of midazolam (3mg) and ketamine (50mg) in a sublingual tablet using Catalent's Zydis® delivery technology. Previous Phase 2 results showed MELT-300 was statistically superior for procedural sedation compared to placebo, midazolam, and ketamine individually.
Harrow (Nasdaq: HROW) has relaunched TRIESENCE®, a preservative-free synthetic corticosteroid approved by the FDA for visualization during vitrectomy and treating ocular inflammatory conditions unresponsive to topical corticosteroids. This relaunch comes after more than five years on the FDA Drug Shortage List and two years of inventory depletion.
Key points:
- TRIESENCE provides a white backdrop against the retina, enhancing visibility during vitrectomy
- It's critical for office-based and surgical procedures
- The relaunch addresses the need for a reliable alternative to less ideal, off-label solutions
- TRIESENCE can be ordered through major pharmaceutical specialty distributors
Ophthalmologists and retina specialists have expressed enthusiasm for the return of this trusted product, highlighting its importance in improving surgical outcomes and patient care.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
What is Harrow Health Inc's primary focus?
What types of products does the company offer?
How does Harrow Health Inc generate revenue?
What differentiates Harrow Health from its competitors?
In which market does Harrow Health primarily operate?
What role does research and development play in the company?
How does the company support clinical practices?
Can you explain the company’s approach to quality assurance?
